Serum Adipokines and Metabolic Parameters With Hormone Replacement in Newly Diagnosed Hypothyroidism

Hypothyroidism is associated with multiple cardiometabolic abnormalities, including dyslipidemia, insulin resistance, adipose tissue dysfunction, altered energy homeostasis, and chronic low-grade inflammation. Although levothyroxine replacement therapy is effective in restoring thyroid hormone levels, metabolic recovery may not occur simultaneously with biochemical normalization of thyroid function.

Adipokines are biologically active molecules secreted by adipose tissue and play important roles in glucose metabolism, lipid regulation, inflammation, and cardiometabolic risk. Among these adipokines, asprosin, adipolin, omentin-1, and visfatin have been associated with insulin resistance, obesity-related metabolic dysfunction, hepatic metabolism, and inflammatory pathways. However, data regarding the dynamic changes of these adipokines after levothyroxine replacement in newly diagnosed primary hypothyroidism remain limited and inconsistent.

This prospective observational study was designed to evaluate changes in serum adipokine levels and metabolic parameters before and after levothyroxine replacement therapy in newly diagnosed primary hypothyroid patients. Serum samples and metabolic measurements will be obtained before treatment initiation and after 8 weeks of levothyroxine therapy.

In addition to conventional thyroid function tests, multiple metabolic indices associated with insulin resistance, lipid metabolism, hepatosteatosis, and cardiometabolic risk will be analyzed, including HOMA-IR, TyG index, METS-IR, AIP, HSI, and Castelli risk indices.

The primary objective of the study is to evaluate changes in adipokine levels following levothyroxine replacement therapy. Secondary objectives include assessing the relationship between adipokine dynamics and metabolic remodeling, insulin resistance, lipid metabolism, obesity phenotype, and hepatic metabolic burden during early biochemical recovery.

Inclusion criteria

• Female patients aged 18 years or older
• Premenopausal status
• Newly diagnosed primary hypothyroidism, defined by elevated serum TSH level above the reference range with low free T4 level
• No previous use of levothyroxine or other thyroid hormone replacement therapy
• Ability and willingness to provide written informed consent
• Completion of both baseline and 8-week follow-up assessments

Exclusion criteria

• Known hypothalamic or pituitary disease
• Previous thyroid hormone replacement therapy
• Pregnancy or lactation
• Menopause
• History of thyroid surgery or radioactive iodine therapy
• Active malignancy
• Acute or chronic inflammatory disease
• Severe hepatic or renal disease
• Diabetes mellitus
• Use of medications known to significantly affect thyroid function, glucose metabolism, lipid metabolism, or adipokine levels
• Inability or unwillingness to provide informed consent or comply with follow-up requirements